Aktana Announces New Strategy Suite to Give Biopharma Leaders Unprecedented Visibility and Control Over Omnichannel Campaign Effectiveness
Today, at the inaugural Aktana Innovation Exchange (AIx) event, Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, announced three new products that transform customer engagement programs by dynamically tightening the connection between strategy, tactical execution and time to impact. AIx is a collaborative event hosting executives from more than 35 life sciences and technology companies with the sole mission of improving the rate of innovation in applying AI and machine learning to commercial and medical programs.
In recent research conducted by Aktana with 20 biopharma companies, more than 75% of respondents cited a severe challenge in achieving direct line of sight of how strategies are being executed in the field and knowing when tactics should be modified.
The gap between strategy and delivering precision execution of pharmaceutical commercial campaigns is a constant hurdle across the industry, with new drug launches failing to meet expectations approximately 34% of the time. To overcome these failures, drug companies need to “think of their drug launch strategy as an organization-wide effort that involves all organizational functions and requires diligent planning and synchronized collaboration,” according to Deloitte.
“What Aktana is introducing will really change the game of how we manage our customer engagement programs, during drug launches and beyond. It has always been a challenge managing our strategies across the organization, and correlating to which tactics are effectively supporting and working with optimal impact," stated a vice president of Commercial Effectiveness at a top 20 pharma company.
The three new products in the strategy suite combine Contextual AI, built-for-use UX, and life sciences domain expertise to deliver intelligent oversight of execution strategy allowing executives to dynamically scale what’s working and reset what’s not.
Strategy Hub: The Single Source of Truth for Omnichannel Execution
Strategy Hub is where leaders for the first time can get a unified and real-time view of omnichannel effectiveness. Strategy Hub allows users the ability to dynamically connect strategies to tactics and track KPIs, while making real-time adjustments to refine and rebalance efforts across all channels. Commercial leaders can immediately see across every channel and update tactics instantly to deliver the most beneficial HCP engagement.
Tactic Genie: Improved Efficiency and Time to Value with the Aid of Gen AI
Tactic Genie utilizes generative AI (a proprietary ensemble of deep reinforcement learning and large language models) to enable operations and effectiveness leaders to analyze and restack their tactic mix toward those that are most effective, with 5-10x faster turnaround than ever before. This powerful tool augments strategic decision-making by identifying underperforming activities and recommending higher-impact opportunities. Commercial and medical teams can collaborate, streamline operations and accelerate time to value.
Impact Simulator: Assessing Effectiveness and Impact in a Low-Risk Environment
Impact Simulator is an AI-powered simulation environment that provides users a virtual platform to evaluate strategies and tactics within the tool before investing broadly and rolling out expensive campaigns. Impact Simulator helps Commercial Operations and Field Medical teams explore and trial scenarios based on real-time data to deliver the most impactful tactics at the right time.
“There is a vast need for AI-enabled solutions that catalyze pharma commercial operations with hyper-personalized and adaptable omnichannel engagement,” said John Vitalie, CEO of Aktana. “Aktana’s Strategy Suite is the first-ever set of tools that provides a unified view of the performance of strategy and tactics, with the ability to simulate and refine outreach in real-time.
“Ultimately, Aktana Strategy Suite enables brand and commercial leaders to deliver pharma launches that are consistently more successful and sustainable.”
Strategy Hub and Tactic Genie will be available to beta customers in the US in Q4 2023, and generally available in Q1 2024. Impact Simulator will be available in Q2 2024.
Aktana’s UX/UI improvement initiative called Glass will begin with the three new strategy suite products and roll out across the entire Aktana product portfolio by March 2025.
Connect with Aktana on LinkedIn: www.linkedin.com/company/aktana
Follow @aktana_inc on Twitter: www.twitter.com/aktana_inc
About Aktana
Aktana is the leader in intelligent customer engagement for the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the world’s top 20 pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more, visit www.aktana.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230926446028/en/
Contact information
Debby Fry Wilson
deborah.wilson@aktana.com
425-638-9617
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Reports Record First-Quarter Revenue9.5.2025 03:12:00 EEST | Press release
Suzano, the world’s largest pulp producer, announces its first quarter results for 2025 (1Q25) with record net revenue of R$11.6 billion, up 22% on the same quarter last year (1Q24). The result was driven by the exchange rates, increased pulp sales volumes from the new Ribas do Rio Pardo mill, higher paper volume and prices and the positive contribution from our paperboard mills recently acquired in the U.S. The record revenues occurred despite a series of planned downtimes in the quarter, including production lines of the Três Lagoas Unit, Mucuri Unit, and Aracruz Unit, and the Ribas do Rio Pardo Unit’s first scheduled maintenance downtime. Sales exceeded 3 million tonnes in the quarter, a rise of 12% compared to 1Q24, comprising 2.7 million tonnes of pulp and 390 thousand tonnes of paper, up 10% and 25%, respectively, on the same quarter last year. Adjusted EBITDA totaled R$4.9 billion, a 7% increase over 1Q24. Operating cash generation totaled R$2.6 billion, rising 5% on 1Q24. Net p
GC Aesthetics® Strengthens Board of Directors with Strategic Appointments8.5.2025 18:10:00 EEST | Press release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets is pleased to announce the appointment of Mr. Luigi Ferrari as Chairman of the Board (non-executive) and Mr. Patrick Lee as Board Director, reinforcing the company’s strategic direction and long-term growth plans. These appointments follow the renewed phase of partnership initiated in early 2024 with Hayfin Capital Management, a longstanding investor in GCA. This collaboration has brought fresh momentum to the company’s commitment to innovation, safety, and global expansion in aesthetic and reconstructive breast surgery. Luigi Ferrari, a seasoned executive and investor with a proven track record in the healthcare sector, brings deep leadership experience, commercial growth expertise and industry insight. From 2012 to 2022 he was CEO of Lima Corporate, a global medical device company in the joint replacement market, acquired then by Enovis Corp
PPG to invest $380 million to build new U.S. manufacturing facility in Shelby, N.C. for aerospace coatings and sealants8.5.2025 17:30:00 EEST | Press release
PPG (NYSE: PPG) today announced that it will invest $380 million to build a new aerospace coatings and sealants manufacturing facility in Shelby, N.C. Construction on the 62-acre site, which will initially include manufacturing and warehousing units, is set to commence in October 2025 and is expected to be completed in the first half of 2027. The 198,000-square-foot facility will enable the company to continue meeting the growing demands of the aerospace industry. It will employ more than 110 people and produce the full line of PPG’s aerospace coatings and sealants. The additional capacity of this new plant, combined with nearby transport links that improve supply chain and shipping logistics, will help improve service levels for customers. “PPG’s investment in this new manufacturing facility demonstrates the significant demand growth for our world-class technologies and our continued commitment to serving our aerospace customers,” said Tim Knavish, PPG chairman and chief executive off
WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features8.5.2025 17:00:00 EEST | Press release
WHOOP, the human performance company, today introduces WHOOP 5.0 and WHOOP MG — two next-generation wearables designed to unlock a new approach to personal health and longevity. Paired with a redesigned WHOOP experience, the devices offer 14-day battery life in a sleeker, seven percent smaller form - and introduce category-defining features, including Healthspan with WHOOP Age, Heart Screener with on-demand ECG, Blood Pressure Insights, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508546933/en/ WHOOP Unveils Next Generation WHOOP® 5.0 and WHOOP® MG These innovations arrive at a pivotal moment when ailing health systems cost more and deliver less. WHOOP is advancing a new solution and a better way - one that empowers people to connect their daily decisions to performance and health outcomes that can be measured and felt. While others track surface-level trends, WHOOP delivers longevity through depth — translati
Seoul Semiconductor Closes in on OSRAM for Global No.28.5.2025 16:00:00 EEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a leading global innovator of LED products and technology, announced that it has achieved a remarkable milestone by maintaining stable growth despite a downturn in the LED industry, narrowing the market share gap with global No.2 player ams OSRAM to just 1 percentage point. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508658995/en/ "2024 Global LED Market Share Rankings" (Source: Omdia) (Image: Seoul Semiconductor) According to the recently published “2024 Global LED Market Share Rankings” by market research firm Omdia, Seoul Semiconductor was the only company among the global top three to sustain both revenue and market share, while industry leaders Nichia and ams OSRAM experienced significant revenue declines amid the market slowdown. This achievement is underpinned by Seoul Semiconductor’s robust technological competitiveness, driven by its commitment to innovation even
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom